Key Highlights

  • Gilead (NASDAQ:GILD) reports after the close on Thursday, October 29, 2026, with consensus earnings per share of USD 2.17, according to one published earnings calendar.
  • Stryker (USD 3.56) and Illumina (USD 1.36) report in the same after-the-bell window, giving healthcare investors a medical-device and life-science read in one evening. Guidance will matter more than the headline numbers.
  • Boston Scientific fell 6% on weak fourth-quarter guidance, which puts guidance, not just EPS, at the centre of how Gilead (NASDAQ:GILD) and its peers are judged.
  • Only EPS consensus figures were retrieved from one calendar page; revenue and guidance expectations were not, so this is a preview to be redone as results.

Three Healthcare Reports After the Close

Gilead Sciences (NASDAQ:GILD) is scheduled to report after the close on October 29, 2026, with consensus earnings per share of USD 2.17. Stryker (NYSE:SYK) has a consensus of USD 3.56. Illumina (NASDAQ:ILMN) is at USD 1.36. These figures come from a single earnings calendar page, and no revenue, product-level or guidance estimates were retrieved. Results were not out when this was written, so everything here is a setup rather than a verdict, and the numbers should be checked against company releases once they appear. Each company covers a different part of the sector: biopharma, medical devices and life-science tools. Healthcare investors will compare each report against that backdrop.

Why Boston Scientific Sets the Tone

Boston Scientific (NYSE:BSX) fell 6% on weak fourth-quarter guidance, as reported. That matters because healthcare names that beat on earnings per share can still fall when forward guidance undershoots, since a share price reflects expected future earnings rather than the quarter just reported. Investors will therefore read Stryker and Illumina for any sign that device and instrument demand is softening, and Gilead (NASDAQ:GILD) for the strength of its guidance. Without revenue and guidance consensus, the USD 2.17 headline number is only part of how the stock will be judged. The reported 6% fall matters because it shows guidance risk is real this season. Investors will also watch for read-through to rival biotechs and device makers.

Risks and What to Watch Next

Macro conditions add risk. The Federal Reserve held at 3.75% to 4.00% on October 28 with two officials preferring a hike, December hike odds are near 81% to 85%, and the 10-year Treasury yield closed above 5%. Higher yields weigh on valuations across long-duration sectors. Nasdaq-100 futures were down about 1.2% before 4:30 a.m. ET. September PCE and third-quarter GDP land at 7:30 a.m. ET. Watch guidance language in each company release, and whether Gilead (NASDAQ:GILD) follows Boston Scientific's cautious tone or breaks from it. Any softer guidance would echo that earlier reaction, while firmer outlooks could break the pattern. Further read-through may come to rivals and suppliers across healthcare. The size of the reaction will depend on how far results and outlooks differ from expectations.

Where Things Stand

Gilead (NASDAQ:GILD) will report USD 2.17 of consensus earnings per share, but what it actually reports, and how the stock reacts, depends on guidance, which has not been published. The evidence so far is a single calendar page and the 6% Boston Scientific fall as a cautionary template. The next catalysts are the three after-the-bell releases from Gilead, Stryker and Illumina, and the morning's PCE and GDP prints.